C
Christine Marosi
Researcher at Medical University of Vienna
Publications - 300
Citations - 36859
Christine Marosi is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Temozolomide. The author has an hindex of 52, co-authored 289 publications receiving 31030 citations. Previous affiliations of Christine Marosi include Vienna General Hospital & University of Vienna.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmström,Bjørn Henning Grønberg,Christine Marosi,Roger Stupp,Didier Frappaz,Henrik Schultz,Ufuk Abacioglu,Björn Tavelin,Benoit Lhermitte,Monika E. Hegi,Johan Rosell,Roger Henriksson +11 more
TL;DR: A randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma found survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy and methylated and unmethylated MGMT promoter treated with radiotherapy.
Journal ArticleDOI
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller,Martin J. van den Bent,Jörg C. Tonn,Roger Stupp,Matthias Preusser,Elizabeth Cohen-Jonathan-Moyal,Roger Henriksson,Emilie Le Rhun,Carmen Balana,Olivier Chinot,Martin Bendszus,Jaap C. Reijneveld,F. Dhermain,Pim J. French,Christine Marosi,Colin Watts,Ingela Oberg,Geoffrey J. Pilkington,Brigitta G. Baumert,Martin J.B. Taphoorn,Monika E. Hegi,Manfred Westphal,Guido Reifenberger,Riccardo Soffietti,Wolfgang Wick,Wolfgang Wick +25 more
TL;DR: The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas, based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline.
Journal ArticleDOI
Prediction of venous thromboembolism in cancer patients
Cihan Ay,Daniela Dunkler,Christine Marosi,Alexandru-Laurentiu Chiriac,Rainer Vormittag,Ralph Simanek,Peter Quehenberger,Christoph C. Zielinski,Ingrid Pabinger +8 more
TL;DR: Clinical and standard laboratory parameters with addition of biomarkers enable prediction of VTE and allow identification of cancer patients at high or low risk of V TE.